Skip to main content

Epivir-HBV Dosage

Generic name: LAMIVUDINE 100mg
Dosage form: tablet, film coated and oral solution
Drug class: Nucleoside reverse transcriptase inhibitors (NRTIs)

Medically reviewed by Last updated on Dec 22, 2021.

HIV Counseling and Testing

HIV counseling and testing should be offered to all patients before beginning treatment with EPIVIR-HBV and periodically during treatment because of the risk of emergence of resistant human immunodeficiency virus type 1 (HIV-1) and limitation of treatment options if EPIVIR-HBV is prescribed to treat chronic hepatitis B infection in a patient who has unrecognized HIV-1 infection or acquires HIV-1 infection during treatment [see Warnings and Precautions (5.2)].

Recommended Dosage for Adult Patients

The recommended oral dosage of EPIVIR‑HBV is 100 mg once daily.

Recommended Dosage for Pediatric Patients

The recommended oral dosage of EPIVIR‑HBV for pediatric patients aged 2 to 17 years is 3 mg per kg once daily up to a maximum daily dosage of 100 mg. The oral solution formulation should be prescribed for patients requiring a dosage less than 100 mg or if unable to swallow tablets.

Patients with Renal Impairment

Dosage recommendations for adult patients with reduced renal function are provided in Table 1 [see Clinical Pharmacology (12.3)].

Table 1. Dosage of EPIVIR-HBV in Adult Patients with Renal Impairment

Creatinine Clearance


Recommended Dosage of EPIVIR-HBV


100 mg once daily


100 mg first dose, then 50 mg once daily


100 mg first dose, then 25 mg once daily


35 mg first dose, then 15 mg once daily


35 mg first dose, then 10 mg once daily

Following correction of the dosage for renal impairment, no additional dosage modification of EPIVIR-HBV is required after routine (4-hour) hemodialysis or peritoneal dialysis [see Clinical Pharmacology (12.3)].

There are insufficient data to recommend a specific dosage of EPIVIR-HBV in pediatric patients with renal impairment.

Important Administration Instructions

EPIVIR-HBV tablets and oral solution may be administered with or without food.
The tablets and oral solution may be used interchangeably [see Clinical Pharmacology (12.3)].
The oral solution should be used for doses less than 100 mg.
EPIVIR-HBV should not be used with other medications that contain lamivudine or medications that contain emtricitabine.

Assessing Patients during Treatment

Patients should be monitored regularly during treatment by a physician experienced in the management of chronic hepatitis B. During treatment, combinations of events such as return of persistently elevated alanine aminotransferase (ALT), increasing levels of HBV DNA over time after an initial decline below assay limit, progression of clinical signs or symptoms of hepatic disease, and/or worsening of hepatic necroinflammatory findings may be considered as potentially reflecting loss of therapeutic response. Such observations should be taken into consideration when determining the advisability of continuing therapy with EPIVIR-HBV.

The optimal duration of treatment, the durability of Hepatitis B e Antigen (HBeAg) seroconversions occurring during treatment, and the relationship between treatment response and long‑term outcomes such as hepatocellular carcinoma or decompensated cirrhosis are not known.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.